TCGA-49-4510-01A-01R-1206-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.430
- COAGULATION+0.350
- ADIPOGENESIS+0.270
- MYOGENESIS+0.240
- PANCREAS_BETA_CELLS+0.230
- KRAS_SIGNALING_DN+0.220
- XENOBIOTIC_METABOLISM+0.180
- FATTY_ACID_METABOLISM+0.170
- BILE_ACID_METABOLISM+0.140
- TGF_BETA_SIGNALING+0.090
Top 10 suppressed
- G2M_CHECKPOINT-0.660
- E2F_TARGETS-0.650
- MYC_TARGETS_V2-0.540
- MITOTIC_SPINDLE-0.530
- MTORC1_SIGNALING-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- MYC_TARGETS_V1-0.390
- INTERFERON_GAMMA_RESPONSE-0.380
- CHOLESTEROL_HOMEOSTASIS-0.290
- HEDGEHOG_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.888 |
| 2 | TCGA-62-A46P-01A-11R-A24H-07 | — | cohortA3 | 0.876 |
| 3 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.857 |
| 4 | TCGA-55-A492-01A-11R-A24H-07 | — | cohortA2 | 0.848 |
| 5 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.844 |
| 6 | TCGA-78-7537-01A-11R-2066-07 | — | cohortA2 | 0.842 |
| 7 | 3d1f44d8-6084-47cb-b57b-099f2cd1fa0e | — | — | 0.837 |
| 8 | TCGA-GM-A2D9-01A-11R-A18M-07 | — | B | 0.827 |
| 9 | SRR29022836 | — | A | 0.826 |
| 10 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |